Nanobiotix (NANO) | Financial Analysis & Statements
Nanobiotix | Mid-cap | Healthcare
Nanobiotix | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
-11.6M
Operating Income
-68.4M
Net Income
-68.1M
EPS (Diluted)
-€1.44
Balance Sheet Metrics
Total Assets
67.4M
Total Liabilities
133.1M
Shareholders Equity
-65.7M
Cash Flow Metrics
Operating Cash Flow
-21.2M
Free Cash Flow
-20.4M
Revenue & Profitability Trend
Nanobiotix Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | -11.6M | 30.1M | 0 | 10.0K | 50.0K |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 59.8M | 60.5M | 50.5M | 54.7M | 38.1M |
| Operating Income | -68.4M | -26.8M | -46.7M | -52.6M | -36.4M |
| Pre-tax Income | -68.0M | -39.6M | -57.0M | -47.0M | -33.6M |
| Income Tax | 101.0K | 120.0K | 10.0K | 5.0K | 9.0K |
| Net Income | -68.1M | -39.7M | -57.0M | -47.0M | -33.6M |
| EPS (Diluted) | -€1.44 | -€1.08 | -€1.64 | -€1.35 | -€1.38 |
Income Statement Trend
Nanobiotix Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 61.5M | 87.3M | 52.4M | 93.1M | 125.2M |
| Non-Current Assets | 6.0M | 6.6M | 7.4M | 8.7M | 8.8M |
| Total Assets | 67.4M | 93.9M | 59.8M | 101.8M | 134.0M |
| Liabilities | |||||
| Current Liabilities | 58.9M | 49.9M | 37.9M | 36.8M | 19.0M |
| Non-Current Liabilities | 74.2M | 45.9M | 48.9M | 38.1M | 44.5M |
| Total Liabilities | 133.1M | 95.7M | 86.8M | 75.0M | 63.6M |
| Equity | |||||
| Total Shareholders Equity | -65.7M | -1.8M | -27.0M | 26.8M | 70.5M |
Balance Sheet Composition
Nanobiotix Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -68.1M | -39.7M | -57.0M | -47.0M | -33.6M |
| Operating Cash Flow | -21.2M | -21.6M | -40.3M | -29.7M | -26.5M |
| Investing Activities | |||||
| Capital Expenditures | -846.0K | -328.0K | -92.0K | -228.0K | -96.0K |
| Investing Cash Flow | -846.0K | -328.0K | -91.0K | -237.0K | -101.0K |
| Financing Activities | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -4.2M | 53.7M | -4.7M | -4.1M | 112.5M |
| Free Cash Flow | -20.4M | -12.8M | -37.2M | -30.1M | -27.6M |
Cash Flow Trend
Nanobiotix Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-2.68
Forward P/E
-3.55
Price to Sales
-24.79
PEG Ratio
-3.55
Profitability Ratios
Profit Margin
0.00%
Operating Margin
271.42%
Return on Equity
103.70%
Return on Assets
-52.89%
Financial Health
Current Ratio
1.04
Debt to Equity
-0.77
Beta
1.56
Per Share Data
EPS (TTM)
-€1.44
Book Value per Share
-€1.39
Revenue per Share
-€0.15
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| nano | 178.2M | -2.68 | - | 103.70% | 0.00% | -0.77 |
| Riber S.A | 65.0M | 15.50 | 2.76 | 18.41% | 10.02% | 16.54 |
| Tronic's | 60.2M | 41.56 | - | -11.75% | 5.36% | -2.08 |
| Société Générale | 37.4B | 8.50 | 0.53 | 4.37% | 19.91% | 4.05 |
| Nokia Oyj | 24.3B | 20.53 | 1.17 | 5.71% | 4.09% | 24.33 |
| Capgemini SE | 24.7B | 14.97 | 2.05 | 15.06% | 7.56% | 51.68 |
Financial data is updated regularly. All figures are in the company's reporting currency.